Find here our press releases and an overview on the coverage of the project in the press.
June 2015
We would like to announce the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the EuroCalin PRS-080 program.
For more information see Pieris press release here.
We would like to announce the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the EuroCalin PRS-080 program.
For more information see Pieris press release here.
January 2015
The clinical trial has started!
For more information see our press release and follow this link to the clinical trials database.
The clinical trial has started!
For more information see our press release and follow this link to the clinical trials database.
June 2014
A paper will be published by RUNMC and Pieris in Clinical Chemistry. The title is "Engineered Human Lipocalin as an Antibody Mimetic: Application to Analysis of the Small Peptide Hormone Hepcidin". You may find the paper here. The authors are Nicolai Grebenchtchikov, Anneke Geurts-Moespot, Stefan Trentmann, Nicole Andersen, Rachida Bel Aiba, Andrea Allersdorfer, Coby Laarakkers, Fred Sweep, Harold Tjalsma, Andreas Hohlbaum and Dorine Swinkels
In frame of the 9th Annual Next Generation Protein Summit Conference, San Francisco, USA, Ulrich Moebius of Pieris gave a presentation on "Multimeric Anticalin® Fusion Proteins with Novel Binding and Targeting Properties".
A paper will be published by RUNMC and Pieris in Clinical Chemistry. The title is "Engineered Human Lipocalin as an Antibody Mimetic: Application to Analysis of the Small Peptide Hormone Hepcidin". You may find the paper here. The authors are Nicolai Grebenchtchikov, Anneke Geurts-Moespot, Stefan Trentmann, Nicole Andersen, Rachida Bel Aiba, Andrea Allersdorfer, Coby Laarakkers, Fred Sweep, Harold Tjalsma, Andreas Hohlbaum and Dorine Swinkels
In frame of the 9th Annual Next Generation Protein Summit Conference, San Francisco, USA, Ulrich Moebius of Pieris gave a presentation on "Multimeric Anticalin® Fusion Proteins with Novel Binding and Targeting Properties".
April 2014
RUNMC will present at the 67th Annual congress of the Dutch Society of Clinical Chemistry 2014, Veldhoven (NL) 9-11th of April. His talk is about "Bioanalytical Assay using an Anticalin®-Protein as Next Generation Antibody Mimetic: Application on the Small Peptide Hormone Hepcidin"; the abstract can be found here .
RUNMC will present at the 67th Annual congress of the Dutch Society of Clinical Chemistry 2014, Veldhoven (NL) 9-11th of April. His talk is about "Bioanalytical Assay using an Anticalin®-Protein as Next Generation Antibody Mimetic: Application on the Small Peptide Hormone Hepcidin"; the abstract can be found here .
October 2013
ConsulTech will present the project at the
Pieris and RUNMC published a joint paper entitled "Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform" in PLoS One; authors are Coby Laarakkers, Erwin Wiegerinck, Siem Klaver, Maria Kolodziejczyk, Hendrik Gille, Andreas Hohlbaum, Harold Tjalsma and Dorine Swinkels
www.plosone.org
ConsulTech will present the project at the
- Biotechnica in Hannover, Germany (8th-10th October)
- Clusterconference in Berlin (23rd October)
- LifeScience Day in Berlin (24th October)
Pieris and RUNMC published a joint paper entitled "Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform" in PLoS One; authors are Coby Laarakkers, Erwin Wiegerinck, Siem Klaver, Maria Kolodziejczyk, Hendrik Gille, Andreas Hohlbaum, Harold Tjalsma and Dorine Swinkels
www.plosone.org
June 2013
Pieris will present new data at the Empowered Antibodies Congress, Barcelona, Spain; the talk is entitled "Applications and success of alternative scaffolds as enabling technologies".
http://www.informa-ls.com/event/adc2013
Pieris will present new data at the Empowered Antibodies Congress, Barcelona, Spain; the talk is entitled "Applications and success of alternative scaffolds as enabling technologies".
http://www.informa-ls.com/event/adc2013
April 2013
Pieris will present new data at the International BioIron Society - 5th Annual Meeting to be held in London UK, April 18th. Andreas Hohlbaum, project leader of EUROCALIN, will give a presentation entitled "IRON MOBILIZATION AND PHARMACODYNIC MARKER MEASUREMENTS IN NON-HUMAN PRIMATES FOLLOWING ADMINISTRATION OF PRS-080, A NOVEL AND HIGHLY SPECIFIC ANTI-HEPCIDIN THERAPEUTIC".
www.bioiron.org
Pieris will present new data at the International BioIron Society - 5th Annual Meeting to be held in London UK, April 18th. Andreas Hohlbaum, project leader of EUROCALIN, will give a presentation entitled "IRON MOBILIZATION AND PHARMACODYNIC MARKER MEASUREMENTS IN NON-HUMAN PRIMATES FOLLOWING ADMINISTRATION OF PRS-080, A NOVEL AND HIGHLY SPECIFIC ANTI-HEPCIDIN THERAPEUTIC".
www.bioiron.org
January 2013
Professor Skerra gave a presentation in Washington DC, USA, at the Phacilitate Protein Therapeutics Forum entitled "Anticalins® & PASylation®: novel concepts for advanced cancer biotherapeutics and beyond"
Professor Skerra gave a presentation in Washington DC, USA, at the Phacilitate Protein Therapeutics Forum entitled "Anticalins® & PASylation®: novel concepts for advanced cancer biotherapeutics and beyond"
November 2012
At the Annual Meeting of the American Society of Nephrology in San Diego, USA
A. Hohlbaum of Pieris presented a poster on "PK/PD-Guided Development of a Novel Hepcidin Antagonist for the Treatment of Functional Iron Deficiency in CKD" (#FR-P0838)
The project was presented in a lecture of Dorine Swinkels of RUNMC in Rio De Janeiro, Brasil, at the HEMO meeting: "Hepcidin in Iron Disorders: Diagnostic Implications"
At the 8th Annual European Antibody Congress in Geneva in Switzerland C. Rothe of Pieris gave a presentation on "Anticalins: Clinical Stage Next Generation Therapeutics with Superior Differentiating Features"
At the Annual Meeting of the American Society of Nephrology in San Diego, USA
A. Hohlbaum of Pieris presented a poster on "PK/PD-Guided Development of a Novel Hepcidin Antagonist for the Treatment of Functional Iron Deficiency in CKD" (#FR-P0838)
The project was presented in a lecture of Dorine Swinkels of RUNMC in Rio De Janeiro, Brasil, at the HEMO meeting: "Hepcidin in Iron Disorders: Diagnostic Implications"
At the 8th Annual European Antibody Congress in Geneva in Switzerland C. Rothe of Pieris gave a presentation on "Anticalins: Clinical Stage Next Generation Therapeutics with Superior Differentiating Features"
August 2012
At the European Iron Club Meeting in Rennes, France, Dorine Swinkels from RUNMC gave a talk entitled "Hepcidin in Iron Disorders: Diagnostic Implications"
At the European Iron Club Meeting in Rennes, France, Dorine Swinkels from RUNMC gave a talk entitled "Hepcidin in Iron Disorders: Diagnostic Implications"
July 2012
The EuroCalin project was presented within Dorine Swinkels (RUNMC) presention "Hepcidin in Iron Disorders: Diagnostic Implications" at the American Association of Clinical Chemistry in Los Angeles, USA
The EuroCalin project was presented within Dorine Swinkels (RUNMC) presention "Hepcidin in Iron Disorders: Diagnostic Implications" at the American Association of Clinical Chemistry in Los Angeles, USA
June 2012
S. Olwill of Pieris held a presentation on will present on "Anticalins - next generation therapeutic proteins" at the Empowered Antibodies Congress in Berlin, Germany see here
In addition, PRS-080 was a topic in the talk "Anticalins: Next Generation Clinical Stage Technology with Applications across Multiple Disease Areas and Targets - oral presentation" at the Next Generation Protein Therapeutics Summit in San Francisco, USA
S. Olwill of Pieris held a presentation on will present on "Anticalins - next generation therapeutic proteins" at the Empowered Antibodies Congress in Berlin, Germany see here
In addition, PRS-080 was a topic in the talk "Anticalins: Next Generation Clinical Stage Technology with Applications across Multiple Disease Areas and Targets - oral presentation" at the Next Generation Protein Therapeutics Summit in San Francisco, USA
Mai 2012
At a conference called "Non Antibody Protein Production" in Prague, Czech Republic, A. Hohlbaum of Pieris gave a talk on "Developing a portable production and purification platform for Anticalins - a clinically validated non-mAb scaffold" see at http://www.informa-ls.com/event/nonantibody2012/workshop
In Munich, on an FP7 workshop organized by the m4 cluster, Dr. Hohlbaum gave a talk on "EUROCALIN - grant application experience"
see here
And also in Munich at the m4 cluster Biobank-Partner meeting
Pieris held a presentation on the "PRS-080 biomarker proposal: Hepcidin plasma levels in patients with anemia of cancer and functional iron deficiency"
www.m4.de
At a conference called "Non Antibody Protein Production" in Prague, Czech Republic, A. Hohlbaum of Pieris gave a talk on "Developing a portable production and purification platform for Anticalins - a clinically validated non-mAb scaffold" see at http://www.informa-ls.com/event/nonantibody2012/workshop
In Munich, on an FP7 workshop organized by the m4 cluster, Dr. Hohlbaum gave a talk on "EUROCALIN - grant application experience"
see here
And also in Munich at the m4 cluster Biobank-Partner meeting
Pieris held a presentation on the "PRS-080 biomarker proposal: Hepcidin plasma levels in patients with anemia of cancer and functional iron deficiency"
www.m4.de
April 2012
At the 103rd Annual Meeting of the American Association for Cancer Research (AACR)in Chicago USA, S.Olwill of Pieris had a poster on "Exploiting the Anticalin therapeutic protein platform for the treatment of cMet ligand-independent and dependent tumors - discovery and characterization of a highly specific and potent c-Met antagonist with drug-like properties" (#3875)
At the 103rd Annual Meeting of the American Association for Cancer Research (AACR)in Chicago USA, S.Olwill of Pieris had a poster on "Exploiting the Anticalin therapeutic protein platform for the treatment of cMet ligand-independent and dependent tumors - discovery and characterization of a highly specific and potent c-Met antagonist with drug-like properties" (#3875)
January 2012
At the 5th Annual Recombinant Antibodies; London, UK, Pieris presented on "Antibody drug conjugates– finally delivering their payload".
At the 5th Annual Recombinant Antibodies; London, UK, Pieris presented on "Antibody drug conjugates– finally delivering their payload".
December 2011
Pieris' Andreas Hohlbaum will give a presentation at the 53rd Annual Meeting of the American Society of Hematology in San Diego, USA; the talk is entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations"
Presentation #40699
Pieris' Andreas Hohlbaum will give a presentation at the 53rd Annual Meeting of the American Society of Hematology in San Diego, USA; the talk is entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations"
Presentation #40699
November 2011
Pieris will present new data at the annual meeting of Amercian Society of Hematalogy to be held in San Diego, USA, December 10 to December 13, 2011. Andreas Hohlbaum, project leader of EUROCALIN, will give a presentation on Monday, December 12, 5 p.m. entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations". The talk will be held in the Elizabeth Ballroom DE (Manchester Grand Hyatt San Diego).
Find here more information about the conference and here more details about the talk.
Let us know if you wish the presentation as pdf.
Pieris will present new data at the annual meeting of Amercian Society of Hematalogy to be held in San Diego, USA, December 10 to December 13, 2011. Andreas Hohlbaum, project leader of EUROCALIN, will give a presentation on Monday, December 12, 5 p.m. entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations". The talk will be held in the Elizabeth Ballroom DE (Manchester Grand Hyatt San Diego).
Find here more information about the conference and here more details about the talk.
Let us know if you wish the presentation as pdf.
News